NPS Pharmaceuticals NPSP and Takeda Pharmaceutical
Company Limited announced today that NPS has
re-gained the full worldwide rights to teduglutide (trade name in
Europe: Revestive®) and recombinant human parathyroid hormone
1-84 (PTH 1-84) (trade name in Europe: Preotact®). NPS
licensed the commercial rights to Preotact and Revestive in 2004 and
2007, respectively, for territories outside of North America to Nycomed,
which was acquired by Takeda in 2011.
Under the terms of the agreement, NPS will have worldwide rights to
develop and commercialize teduglutide and PTH 1-84. Takeda will also
assign to NPS its assets related to the two products, including all of
its active pharmaceutical ingredient inventory
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in